Molsidomin Heumann (Molsidomine)

Molsidomine is a prodrug that is converted to linsidomine after oral absorption. Linsidomine releases nitric oxide, a potent vasodilator, which activates guanylate cyclase in vascular smooth muscle. The resulting increase in cyclic GMP causes relaxation of blood vessels, lowering cardiac preload and afterload and decreasing myocardial oxygen demand.

The dosage of Molsidomin Heumann is individualized by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. The prescriber determines the appropriate strength, frequency, and duration of therapy in accordance with local guidelines and product labeling.

Safety data for molsidomine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women, and alternative therapies may be considered.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Molsidomine belongs to the nitric oxide donor class, offering vasodilation without the rapid tolerance seen with some nitrates. Compared with beta‑blockers or calcium‑channel blockers, it primarily reduces myocardial oxygen demand through vascular relaxation rather than heart‑rate control, making it a useful adjunct or alternative in patients who cannot tolerate other agents.

Molsidomin Heumann tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Protect them from moisture, humidity, and direct sunlight to maintain stability. No refrigeration is required for this oral tablet formulation.

The medication is taken orally as a tablet, usually with or without food as directed by the prescriber. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule provided by their healthcare professional.

The most serious adverse events include severe hypotension that can lead to syncope, rare allergic reactions such as rash or anaphylaxis, and, in uncommon cases, myocardial infarction or significant liver enzyme elevations. Patients should seek immediate medical attention if they experience fainting, chest pain, or signs of an allergic reaction.

Molsidomin Heumann is contraindicated in patients with known hypersensitivity to molsidomine or any of its excipients, and in those who are currently using other nitrate preparations due to the risk of additive hypotension. Caution is also advised for individuals with severe hepatic impairment or uncontrolled hypotension.